Patrick Yue is a Cardiology physician affiliated with Phusis Therapeutics. OpenAlex indexes 81 publications with 3,806 citations (h-index 29); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3801 Miranda Ave
Palo Alto, CA 943041207
Telephone
650-723-8222Registry record last updated 2 Nov 2011.
Clinical trials
- GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
Sponsor: Gilead Sciences
- Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Sponsor: Gilead Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Melinta Therapeutics, LLCProgram year20252 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2004–2011 per NIH RePORTER. The latest:
- The Role of the Cardioactive Peptide Apelin in Adipocyte Signaling
Stanford University
FY2011$151,319K08DK080463 - The Role of the Cardioactive Peptide Apelin in Adipocyte Signaling
Stanford University
FY2010$151,319K08DK080463 - The Role of the Cardioactive Peptide Apelin in Adipocyte Signaling
Stanford University
FY2009$151,319K08DK080463
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
Journal of the American College of Emergency Physicians Open
2022 - Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
Thrombosis and Haemostasis
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”